US Oncology Affiliated Physicians to Present and Receive Honors at ASCO

More than 50 Physicians and Oncology Experts Affiliated with US Oncology Presenting Orals, Posters and Poster Discussions

News provided by

US Oncology, Inc.

May 20, 2010, 07:13 ET

THE WOODLANDS, Texas, May 20 /PRNewswire/ -- US Oncology, Inc., the nation's leading integrated oncology company, announced today that two physicians affiliated with US Oncology Research will be honored at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) held June 4 - 8 at McCormick Place in Chicago.

(Photo: http://www.newscom.com/cgi-bin/prnh/20100520/DA08694)

Daniel D. Von Hoff, MD, FACP, is the recipient of the 2010 David A. Karnofsky Memorial Award and Lecture for his outstanding achievements in cancer research and for his impact on the treatment of patients with cancer. Dr. Von Hoff is an internationally recognized physician-scientist who has contributed to the development of numerous anticancer agents, including paclitaxel, docetaxel, irinotecan and gemcitabine. He currently serves as physician-in-chief for the Translational Genomics Institute in Phoenix, Arizona, chief scientific officer at US Oncology and Scottsdale Healthcare, and clinical professor of medicine at The University of Arizona College of Medicine. Dr. Von Hoff also serves as lead physician of the Translational Oncology Program (TOP) for US Oncology. The TOP program offers Phase I clinical trial studies, which often offer first-in-human agents. He is also responsible for bringing many new compounds to US Oncology Research for studies.

John V. Cox, DO, FACP, Texas Oncology is a recipient of the ASCO Statesman Award. This award recognizes ASCO members for their extraordinary volunteer service, dedication, and commitment to ASCO. Recipients of the 2010 Statesman Award have given 20 years of volunteer service.

In addition, more than 50 physicians affiliated with US Oncology Research and the United Network of US Oncology participated in studies that will be presented in oral and poster presentations at this year's ASCO. US Oncology Research has a long history of bringing innovative and successful agents to market. To date, US Oncology Research has played a role in the development of 40 FDA approved cancer fighting therapies.

Presentations that US Oncology affiliated physicians are part of include:

Oral Abstracts:
Joyce O'Shaughnessy, MD, Texas Oncology - Baylor Sammons Cancer Center:
	Tuesday, June 08, 9:30AM – 12:30 PM (10:45 AM) E Hall D1
	A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC)

Joanne Blum, MD, PhD, Texas Oncology - Baylor Sammons Cancer Center
	Tuesday, June 08, 9:30 AM – 12:30 PM (9:30 AM) E Hall D1
	A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane.

Jeff Sharman, MD, Willamette Valley Cancer Institute and Research Center;
Kathryn Kolibaba, MD, Northwest Cancer Specialists - Vancouver Cancer Center
Thomas Boyd, MD, North Star Lodge Cancer Center, Yakima, Wash.
	Saturday, June 05, 1:00 – 4:00 PM (3:45 PM) E354a
	Effect of BTK inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study

William R. Berry, MD, Cancer Centers of North Carolina - Raleigh
	Sunday, June 06, 9:30 AM – 12:30 PM (11:15 AM) E Hall D2
	Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): Results from the phase III ASCENT2 trial.


Late Breaking Oral Presentation:
Michael G. Teneriello, MD, Texas Oncology - Austin Central
	Sunday, June 06, 9:30 AM – 12:30 PM (11:45 AM) E Arie Crown Theater
	Phase III trial of induction gemcitabine (G) or paclitaxel (T) plus carboplatin (C) followed by elective T consolidation in advanced ovarian cancer (OC): Final safety and efficacy report.


Clinical Science Symposium:
Daniel D. Von Hoff, MD, FACP, US Oncology Research and Translational Genomics Research Institute (TGen)
	Sunday, June 06, 8:00 AM – 9:30 AM (8:45 AM) E345a
	Phase I dose-escalation study of E6201, a MEK-1 inhibitor, in advanced solid tumors.


Donald A. Richards, MD, PhD, Texas Oncology – Tyler
	Monday, June 07, 9:45 AM – 11:15 AM (10:15 AM) E Arie Crown Theater
	Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: Final data from a multicenter phase II study.


Poster Discussions:
Michael G. Teneriello, MD, Texas Oncology - Austin Central
	Poster #5 Sunday , June 06, 2:00 PM – 6:00 PM E450a
	Discussion 5:00 PM – 6:00 PM E Arie Crown Theater
	PRECEDENT: a randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer Poster discussion

Mark Fleming, MD, Virginia Oncology Associates - Hampton
Michael Kolodziej, MD, New York Oncology Hematology - Albany Medical Center
Sanjay Awasthi, MD, Texas Oncology - Arlington South
Thomas E. Hutson, DO, PharmD, Texas Oncology - Baylor Sammons Cancer Center
Danko Martincic, MD, Cancer Care Northwest – Spokane Valley
Guru Sonpavde, MD, Texas Oncology - Deke Slayton Cancer Center
Yunfei Wang; Kristi A. Boehm; Lina Asmar, PhD: US Oncology Research
	Poster #12 Monday, June 07, 8:00 AM – 12:00 PM 450a
	Discussion 12 – 1 PM E Hall D2
	Results of a randomized phase II study of mitoxantrone vs mitoxantrone with cetuximab in metastatic castrate resistant prostate cancer previously treated with docetaxel-based chemotherapy. Poster discussion

Donald A. Richards, MD, PhD, Texas Oncology – Tyler
Joe Stephenson, MD, Cancer Centers of The Carolinas
Lawrence E. Garbo, MD, New York Oncology Hematology - Albany Medical Center
	Poster #23 Friday, June 04, 2:00PM - 6:00PM E 450b
	Discussion 5:00 – 6:00 PM E354a
	A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC).

Donald A. Richards, MD, PhD, Texas Oncology - Tyler
	Poster #22 Tuesday, June 08, 8:00 AM - 12:00 PM S403
	Discussion 11:00 AM – 12:00 PM S406 (Vista room)
	Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second- or third-line metastatic colorectal cancer (mCRC).

Donald A. Richards, MD, PhD, Texas Oncology - Tyler
Lawrence E. Garbo, MD, New York Oncology Hematology
Joe Stephenson, MD, Cancer Centers of The Carolinas
	Poster #23 Friday, June 04, 2:00 PM - 6:00 PM E450b
	Discussion 5:00 PM – 6:00 PM E354a
	A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC).

Robert N. Raju, MD, Dayton Oncology & Hematology – Kettering
	Poster #15 Saturday, June 05, 8:00 AM - 12:00 PM E450a
	Discussion 12:00 PM – 1:00 PM E354a
	A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered once weekly in patients with solid tumors.

Michael G. Teneriello, MD, Texas Oncology - Austin Central
	Poster #5 Sunday, June 06, 2:00 PM – 6:00 PM E450a
	Discussion 5:00 PM – 6:00 PM E Arie Crown Theater
	PRECEDENT: a randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer

Patrick J. Flynn, MD, Minnesota Oncology - Minneapolis
	Poster #1 Tuesday, June 08, 8:00 AM – 12:00 PM E450a
	Discussion 11:00 AM – 12:00 PM E353
	Evaluation of a urea/lactic acid-based topical keratolytic agent (ULABTKA) for prevention of capecitabine-induced hand and foot syndrome (HFS): NCCTG trial N05C5.

Patrick J. Flynn, MD, Minnesota Oncology - Minneapolis
	Poster #10 Saturday, June 05, 8:00 AM - 12:00 PM S103
	Discussion 12:00 PM – 1:00 PM S100b
	NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM


General Posters:
Matthew Galsky, MD, Comprehensive Cancer Centers of Nevada - Twain
Guru Sonpavde, MD, Texas Oncology - Deke Slayton Cancer Center
Beth Hellerstedt, MD, Texas Oncology - Austin Central
Scott McKenney, MD, Texas Oncology - Mamie McFadden Ward Cancer Center Beaumont
Thomas E. Hutson, DO, PharmD, Texas Oncology - Baylor Sammons Cancer Center
Mary A. Rauch; Yunfei Wang; Kristi A. Boehm; Lina Asmar, PhD: US Oncology Research
	Poster #1H Monday, June 07, 1:00 PM – 5:00 PM S Hall A2
	Phase II study of gemcitabine, cisplatin, and sunitinib in patients with advanced urothelial carcinoma.

David McCollum, MD, Texas Oncology - Baylor Sammons Cancer Center
Darren M. Kocs, MD, Texas Oncology - Round Rock
Punit Chadha, MD, Texas Oncology - South Austin
Donald A. Richards, MD, PhD, Texas Oncology – Tyler
Yunfei Wang; Kristi A. Boehm; Lina Asmar, PhD: US Oncology Research
	Poster #14D Sunday, June 06, 2:00 PM - 6:00 PM S Hall A2
	A randomized Phase II trial of preoperative chemoradiotherapy with or without cetuximab in locally-advanced adenocarcinoma of the rectum.

Thomas H. Cartwright, MD, Ocala Oncology Center
Matthew Clayton; Jody Garey, PharmD; Kristi A. Boehm, US Oncology Research on behalf of US Oncology Pathways Task Force
	Poster #13C Sunday, June 06, 2:00 PM - 6:00 PM S Hall A2
	Use of an Electronic Health Record (iKnowMed), in conjunction with evidence-based pathways, permits more complete data capture for outcome measurement in colorectal cancer patients treated with 1st-line therapy in the US Oncology network.

Marcus A. Neubauer, MD, Kansas City Cancer Center - Southwest
Debra A. Patt, MD, Texas Oncology - Austin Central
Janet L. Espirito, PharmD; Matthew Clayton; US Oncology Pathways Task Force
	Poster #27G Monday, June 07, 1:00 PM – 5:00 PM S Hall A2
	Combination vs. sequential chemotherapy for metastatic breast cancer: An evaluation of outcomes from a community oncology network.

Susan N. Hoang, PharmD; Innovent Oncology
J. Russell Hoverman, MD, Texas Oncology
Brian Turnwald; US Oncology Pathways Task Force
	Poster #34A Monday, June 07, 1:00 PM – 5:00 PM S Hall A2
	2nd line pancreatic cancer therapy: Patterns of care and survival.

Thomas E. Hutson, DO, PharmD, Texas Oncology - Baylor Sammons Cancer Center
	Poster #7A Monday, June 07, 1:00 PM – 5:00 PM S Hall A2
	Long-term sorafenib safety profile in > 700 patients with renal cell carcinoma treated for 12 to 42 months.

Thomas E. Hutson, DO, PharmD, Texas Oncology - Baylor Sammons Cancer Center
	Poster #5H Monday, June 07, 1:00 PM – 5:00 PM S Hall A2
	Sorafenib (SOR) safety profile in >4600 patients (pts) with renal cell carcinoma (RCC): assessment at 3-month (mo) intervals using an integrated database of 8 company-sponsored studies

Steve K. Gruschkus, PhD; Clara Chen; Michael T. Forsyth: US Oncology
	Poster #20C Saturday, June 05 2:00 PM – 6:00 PM S Hall A2

	First line patterns of care and outcomes of HER2 (+) breast cancer patients who progressed after receiving adjuvant trastuzumab in the outpatient community setting.

J. Russell Hoverman, MD, Texas Oncology
Steve K. Gruschkus, PhD; Michael T. Forsyth; Clara Chen: US Oncology
	Poster #35D Monday, June 07, 1:00 PM – 5:00 PM S Hall A2
	Impact of comorbidities on clinical and economic outcomes among patients with advanced non-small cell lung cancer (NSCLC) receiving care in the community-based outpatient setting.

Mary Ann K. Allison, MD, Comprehensive Cancer Centers of Nevada
	Poster #14D Monday, June 07, 8:00 AM – 12:00 PM S Hall A2
	Phase I study of PD 0332991, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole for first-line treatment of patients with ER-positive, HER2-negative breast cancer.

Allen L. Cohn, MD, Rocky Mountain Cancer Centers
	Poster #8F Saturday, June 05 2:00 PM – 6:00 PM S Hall A2
	Bevacizumab (BV) plus chemotherapy (CT) in second-line metastatic colorectal cancer (mCRC): Initial results from ARIES, a second BV observational cohort study (OCS).

Joyce O'Shaughnessy, MD, Texas Oncology - Baylor Sammons Cancer Center
Jessica D. Jensen; Lina Asmar, PhD: US Oncology Research
	Poster #24A Saturday, June 05, 2:00 PM – 6:00 PM S Hall A2
	Candidate predictive biomarkers of cetuximab benefit in triple-negative breast cancer

Allen L. Cohn, MD, Rocky Mountain Cancer Centers
	Poster #8G Saturday, June 05 2:00 PM – 6:00 PM S Hall A2
	Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP).

Thomas E. Hutson, DO, PharmD, Texas Oncology - Baylor Sammons Cancer Center
	Poster #4E Monday, June 07, 1:00 PM – 5:00 PM S Hall A2
	TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase 3 trial of sunitinib vs. interferon-alfa (IFN-a)

Nicholas Robert, MD, Fairfax-Northern Virginia Hematology-Oncology
	Poster #17H Saturday, June 05, 2:00 PM – 6:00 PM S Hall A2
	Efficacy of capecitabine (C)-based therapy in patients with first-line metastatic breast cancer (MBC) previously treated with adjuvant anthracyclines and taxanes.

Daniel Von Hoff, MD, FACP, US Oncology Research and Translational Genomics Research Institute (TGen)
	Poster #1C Monday, June 07, 8:00 AM – 12:00 PM S Hall A2
	A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors.

Guru Sonpavde, MD, Texas Oncology - Deke Slayton Cancer Center
	Poster #2C Monday, June 07, 8:00 AM – 12:00 PM S Hall A2
	Correlation of disease-free survival at 2 to 3 years and 5-year overall survival in patients with muscle-invasive bladder cancer undergoing radical cystectomy.

Daniel Von Hoff, MD, FACP, US Oncology Research and Translational Genomics Research Institute (TGen)
	Poster #5F Monday, June 07, 8:00 AM – 12:00 PM S Hall A2
	Final results from a phase I study of oral TRC102 (methoxyamine HCl), an inhibitor of base-excision repair, to potentiate the activity of pemetrexed in patients with refractory cancer.

Daniel Von Hoff, MD, FACP, US Oncology Research and Translational Genomics Research Institute (TGen)
	Poster #16D Monday, June 07, 8:00 AM – 12:00 PM S Hall A2
	Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1a.

Daniel Von Hoff, MD, FACP, US Oncology Research and Translational Genomics Research Institute (TGen)
	Poster #25F Monday, June 07, 1:00 PM – 5:00 PM S Hall A2
	Concomitant medication (CM) use in phase I and II cancer clinical trials(CCT): Effects on trial eligibility and potential interactions with study medications.

Patrick J. Flynn, MD, Minnesota Oncology - Minneapolis
	Poster #21A Saturday, June 05, 8:00 AM – 12:00 PM S Hall A2
	Phase II study of the histone deacetylase (HDAC) inhibitor belinostat for the treatment of myelodysplastic syndrome (MDS).

Guru Sonpavde, MD, Texas Oncology - Deke Slayton Cancer Center
William R. Berry, MD, Cancer Centers of North Carolina - Raleigh
	Poster #9H Monday, June 07, 1:00 PM – 5:00 PM S Hall A2
	Use of changes in serum alkaline phosphatase to predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy: A retrospective analysis of the TAX327 trial.

Joyce O'Shaughnessy, MD, Texas Oncology - Baylor Sammons Cancer Center
	Poster #21E Saturday, June 05, 2:00 PM – 6:00 PM S Hall A2
	Differential gene expression analysis and correlation with outcome in HER2-positive metastatic breast cancer treated with HER2-targeted therapy.

Thomas E. Hutson, DO, PharmD, Texas Oncology - Baylor Sammons Cancer Center
	Poster #6C Monday, June 07, 1:00 PM – 5:00 PM S Hall A2
	Efficacy and safety of everolimus in elderly patients (pts) with metastatic renal cell carcinoma (mRCC).

Karen L. Tedesco, MD, New York Oncology Hematology - Amsterdam
Joanne L. Blum, MD, PhD, Texas Oncology - Baylor Sammons Cancer Center
Cynthia R. Osborne, MD, Texas Oncology - Baylor Sammons Cancer Center
Frankie Ann Holmes, MD, Texas Oncology - Houston Memorial City
	Poster #21G Saturday, June 05, 2:00 PM – 6:00 PM S Hall A2
	A phase II trial of trabectedin (T) in patients (pts) with HER2-positive and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC).


Trials in Progress:
Frankie Ann Holmes, MD, Texas Oncology - Houston Memorial City
Joyce O'Shaughnessy, MD, Texas Oncology - Baylor Sammons Cancer Center
	Poster #21F Monday, June 07, 8:00 AM - 12:00 PM S Hall A2
	Lapatinib and trastuzumab: Molecular effects and efficacy, separately and combined in breast cancer.

Allen L. Cohn, MD, Rocky Mountain Cancer Centers
	Poster #36H Monday, June 07, 8:00 AM - 12:00 PM S Hall A2
	SPIRITT: a multi-center, open label, randomized, phase 2 clinical trial evaluating safety and efficacy of FOLFIRI with either panitumumab or bevacizumab as second-line treatment in patients with metastatic colorectal cancer (mCRC) with wild-type KRAS tumors.

Allen L. Cohn, MD, Rocky Mountain Cancer Centers
	Poster #41 Monday, June 07, 8:00 AM - 12:00 PM S Hall A2
	A randomized, placebo-controlled, multicenter phase II adjuvant trial of the efficacy, immunogenicity, and safety of GI-4000 plus gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer with activating ras mutations.

Joyce O'Shaughnessy, MD, Texas Oncology - Baylor Sammons Cancer Center
Gail Wright, MD, Florida Cancer Institute-New Hope - Hudson
	Poster #24F Monday, June 07, 8:00 AM - 12:00 PM S Hall A2
	Three parallel randomized phase 2 trials of dasatinib plus hormonal therapy (HT) in advanced ER+ breast cancer (ER+ BC)


Publish Only
Sheetal Sheth, PharmD, Innovent Oncology
J. Russell Hoverman, MD, Texas Oncology
Brian Turnwald, US Oncology on behalf of US Oncology Pathways Task Force
	Cytotoxic therapy beyond 2nd-line in non-small cell lung cancer: patterns of care and survival.

Clara Chen; Steve K. Gruschkus, PhD; US Oncology
Nicholas J. Vogelzang, MD, Comprehensive Cancer Centers of Nevada
Thomas E. Hutson, DO, PharmD, Texas Oncology - Baylor Sammons Cancer Center
Michael T. Forsyth; William Lopez: US Oncology
	Observational study evaluating resource utilization among metastatic renal cell carcinoma patients treated with mTOR inhibitors in the outpatient community-based setting.

About US Oncology

US Oncology, Inc. is the nation's leading integrated oncology company. By uniting the largest community-based cancer treatment and research network in America, US Oncology expands patient access to high-quality care and advances the science of cancer care. Headquartered in The Woodlands, Texas, US Oncology is affiliated with more than 1,300 community-based oncologists, and works with patients, hospitals, payers, and the medical industry across all phases of the cancer research and delivery continuum. By promoting the use of innovative technology, clinical research, evidence-based medicine and shared best practices, US Oncology improves patient outcomes and offers a better patient experience. For more information, visit www.usoncology.com.

About US Oncology Research

US Oncology conducts clinical research through US Oncology Research, its wholly-owned subsidiary and the nation's largest community-based cancer research network. US Oncology Research has experienced investigators and dedicated research nurses who specialize in Phase I through Phase IV oncology clinical trials. US Oncology Research serves more than 80 sites in 200 locations managing more than 200 active trials at any given time. The research network has enrolled more than 42,900 patients in more than 700 trials since its inception and has contributed to the development of 40 cancer therapies approved by the FDA. For more information call (866) 216-5053 or visit www.usoncology.com/oncologists.

SOURCE US Oncology, Inc.